Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
ACT-AD: Fosgonimeton in mild-to-moderate Alzheimer's disease - first results of a randomized, placebo-controlled, 26-week Phase 2 proof-of-concept trial
Alzheimer's & Dementia · Vol. 18 Published January 1, 2022
More on these topics
Browse all publications →-
2026 · Alzheimers Dement.
Evaluating digital cognitive tests for clinical use in Alzheimer's disease: A novel framework and scoping review
-
2026 · Stat Med.
Time-Scale Target Parameters and Two-Step Estimation in Longitudinal Trials for Progressive Diseases
-
2026 · Nat Med
Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease
-
2026 · Alzheimers Dement
Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography: Results from Bio-Hermes Study participants